Predictors ID'd for Switching to Active Tx in Prostate Cancer

This article originally appeared here.
Share this content:
Predictors ID'd for Switching to Active Tx in Prostate Cancer
Predictors ID'd for Switching to Active Tx in Prostate Cancer

TUESDAY, Aug. 2, 2016 (HealthDay News) -- For men with low-risk prostate cancer, factors such as ethnicity influence patient decision to pursue active treatment during active surveillance, according to a study published online in The Journal of Urology.

Scott P. Kelly, Ph.D., from the Georgetown University Medical Center in Washington, D.C., and colleagues conducted a retrospective study involving 2,228 men diagnosed with low-risk prostate cancer who did not receive treatment within the first year of diagnosis. Factors associated with time from diagnosis to active treatment were examined.

The researchers found that 27 percent of the men began active treatment at a median of 2.9 years during follow-up. Compared with non-Hispanic white men, non-Hispanic black men were marginally more likely to begin active treatment, independent of baseline and follow-up clinical measures (hazard ratio [HR], 1.3; 95 percent confidence interval [CI], 1.0 to 1.7). Among those who remained on observation, rebiopsy within 24 months of diagnosis occurred at a slightly lower rate for non-Hispanic black than non-Hispanic white men (HR, 0.70; 95 percent CI, 0.60 to 1.0). Independent of race, Gleason grade progression (HR, 3.3; 95 percent CI, 2.7 to 4.1) and prostate-specific antigen doubling time less than 48 months (HR, 2.9; 95 percent CI, 2.3 to 3.7) correlated with active treatment initiation.

"Sociodemographic factors such as ethnicity and education may independently influence the patient decision to pursue active treatment and serial biopsies during active surveillance," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths